JP2017519768A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519768A5
JP2017519768A5 JP2016573926A JP2016573926A JP2017519768A5 JP 2017519768 A5 JP2017519768 A5 JP 2017519768A5 JP 2016573926 A JP2016573926 A JP 2016573926A JP 2016573926 A JP2016573926 A JP 2016573926A JP 2017519768 A5 JP2017519768 A5 JP 2017519768A5
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
binding fragment
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016573926A
Other languages
English (en)
Japanese (ja)
Other versions
JP6845016B2 (ja
JP2017519768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/036576 external-priority patent/WO2015196011A1/en
Publication of JP2017519768A publication Critical patent/JP2017519768A/ja
Publication of JP2017519768A5 publication Critical patent/JP2017519768A5/ja
Application granted granted Critical
Publication of JP6845016B2 publication Critical patent/JP6845016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016573926A 2014-06-19 2015-06-19 多細菌性感染の治療 Active JP6845016B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462014506P 2014-06-19 2014-06-19
US62/014,506 2014-06-19
US201562140849P 2015-03-31 2015-03-31
US62/140,849 2015-03-31
PCT/US2015/036576 WO2015196011A1 (en) 2014-06-19 2015-06-19 Treatment of polybacterials infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020209896A Division JP2021063090A (ja) 2014-06-19 2020-12-18 多細菌性感染の治療

Publications (3)

Publication Number Publication Date
JP2017519768A JP2017519768A (ja) 2017-07-20
JP2017519768A5 true JP2017519768A5 (cg-RX-API-DMAC7.html) 2018-08-09
JP6845016B2 JP6845016B2 (ja) 2021-03-17

Family

ID=54936121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016573926A Active JP6845016B2 (ja) 2014-06-19 2015-06-19 多細菌性感染の治療
JP2020209896A Pending JP2021063090A (ja) 2014-06-19 2020-12-18 多細菌性感染の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020209896A Pending JP2021063090A (ja) 2014-06-19 2020-12-18 多細菌性感染の治療

Country Status (11)

Country Link
US (1) US11168132B2 (cg-RX-API-DMAC7.html)
EP (1) EP3157565B1 (cg-RX-API-DMAC7.html)
JP (2) JP6845016B2 (cg-RX-API-DMAC7.html)
KR (1) KR102549870B1 (cg-RX-API-DMAC7.html)
CN (1) CN106456767B (cg-RX-API-DMAC7.html)
AU (1) AU2015276938B2 (cg-RX-API-DMAC7.html)
CA (1) CA2952278A1 (cg-RX-API-DMAC7.html)
ES (1) ES2983252T3 (cg-RX-API-DMAC7.html)
SG (2) SG11201609652RA (cg-RX-API-DMAC7.html)
TW (1) TWI719938B (cg-RX-API-DMAC7.html)
WO (1) WO2015196011A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2718320T (lt) 2011-06-10 2018-04-10 Medimmune Limited Anti-pseodomonas psl surišančios molekulės ir jų panaudojimas
MX374826B (es) 2011-11-07 2025-03-06 Medimmune Llc Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas.
KR102272744B1 (ko) 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
EP3640338A1 (en) * 2012-11-06 2020-04-22 Medlmmune, LLC Antibodies to s. aureus surface determinants
WO2017095744A1 (en) 2015-11-30 2017-06-08 Medimmune, Llc Method for preventing or treating nosocomial pneumonia
KR20190025826A (ko) * 2016-05-05 2019-03-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
BR112021001214A2 (pt) 2018-07-24 2021-04-27 Medimmune, Llc anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus
CN113015745B (zh) 2018-10-09 2025-02-11 免疫医疗有限责任公司 针对金黄色葡萄球菌白细胞毒素的抗体
US11168133B2 (en) 2018-10-09 2021-11-09 Medimmune, Llc Combinations of anti-Staphylococcus aureus antibodies
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
WO2020185986A1 (en) * 2019-03-13 2020-09-17 Medimmune, Llc Decreasing staphylococcus aureus infections in colonized patients
MX2021015156A (es) * 2019-06-11 2022-01-18 Regeneron Pharma Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
US20220259290A1 (en) * 2019-07-24 2022-08-18 Japan Science And Technology Agency Innovative production technique for antibody-enzyme
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2025117765A1 (en) * 2023-12-01 2025-06-05 University Of Washington Protective monoclonal antibodies to pseudomonas aeruginosa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043690A1 (en) 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
CA2784033A1 (en) 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
CN107474133B (zh) 2011-02-08 2021-10-15 米迪缪尼有限公司 特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法
MX374826B (es) * 2011-11-07 2025-03-06 Medimmune Llc Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas.
SG11201502937PA (en) * 2012-11-06 2015-06-29 Medimmune Llc COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES
KR102272744B1 (ko) 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
EP3640338A1 (en) 2012-11-06 2020-04-22 Medlmmune, LLC Antibodies to s. aureus surface determinants
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody

Similar Documents

Publication Publication Date Title
JP2017519768A5 (cg-RX-API-DMAC7.html)
JP2021063090A5 (cg-RX-API-DMAC7.html)
King Bronchiectasis
JP6845016B2 (ja) 多細菌性感染の治療
DiGiandomenico et al. Antibacterial monoclonal antibodies: the next generation?
Sulakvelidze et al. Bacteriophages as therapeutic agents
US11911472B2 (en) Monoclonal antibody and vaccine targeting filamentous bacteriophage
Munita et al. Enterococcal endocarditis: can we win the war?
JP2016507470A5 (cg-RX-API-DMAC7.html)
JP2013515079A5 (cg-RX-API-DMAC7.html)
HRP20201370T1 (hr) Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
Bezáková et al. Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants
RU2016116949A (ru) Анти-лпс о11-антитело
JP2018529661A5 (cg-RX-API-DMAC7.html)
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
JP2012516897A5 (cg-RX-API-DMAC7.html)
CN111372603A (zh) 针对铜绿假单胞菌感染的组合物和方法
JP2008526848A (ja) 黄色ブドウ球菌感染を治療する方法
Binar et al. An unusual cause of necrosis and nasal septum perforation after septoplasty: Enterobacter cloacae
Tur Clinical Microbiology and Infectious Diseases (ECCMID)-28th European Congress. Madrid, Spain-April 21-24, 2018
Koff et al. Clinical use of inhaled bacteriophages to treat multi-drug resistant Pseudomonas aeruginosa
Kim et al. Infective endocarditis prophylaxis before dental procedures: New guidelines spark controversy
Projan Antibodies for the Prevention, Treatment, and Preemption of Infectious Diseases
Tümmler aeruginosa [version 1; peer review: 2 approved]
AI Valasidis et al. Novel antimicrobial agents for the management of maxillofacial and neck infections